Sign In / Register
Human Phospho-VEGFR2/KDR DuoSet IC ELISA
Catalog # DYC1766-2 | R&D Systems, Inc. a Bio-Techne Brand
Loading...
Key Product Details
| Assay Type: | Solid Phase Sandwich ELISA |
| Sample Types: | Cell Lysates |
| Human Phospho-VEGFR2/KDR DuoSet IC ELISA Features: |
|
Customers also Viewed
Customers also Purchased
|
|
Figure 1. The Human Phospho-VEGF R2 DuoSet IC ELISA is more sensitive than immunoprecipiation (IP)-Western blot analysis Human umbilical vein endothelial cells (HUVEC) were treated with 100 ng/mL recombinant human VEGF165 (Catalog # 293-VE) for five minutes to induce tyrosine phosphorylation of VEGF R2. Dilutions of HUVEC lysates were analyzed by this ELISA (Catalog # DYC1766) and IP-Western blot (inset). IPs were performed using an anti-VEGF R2 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with a biotinylated anti-phospho-tyrosine monoclonal antibody (Catalog # BAM1676) to detect phospho-VEGF R2 (p-VEGF R2). Bands were visualized with Streptavidin-HRP (Catalog # DY998) followed by chemiluminescent detection. Blots were stripped and total VEGF R2 (VEGF R2) was detected using a biotinylated polyclonal anti-VEGF R2 antibody (Catalog # BAF357). |
|
|
Figure 2. The Human Phospho-VEGF R2DuoSet IC ELISA detects ligand-induced VEGF R2 tyrosine phosphorylation HUVECs were untreated or treated with 100 ng/mL recombinant human VEGF165 for five minutes. ELISA and IP-Western blot (inset) analyses were performed using 100 μg and 1000 μg of lysate, respectively. IP-Western blots were performed as described in Figure 1. |
|
|
Figure 3. The specificity of the Human Phospho-VEGF R2DuoSet IC ELISA is confirmed by receptor competition HUVECs were treated with 100 ng/mL of human recombinant VEGF165 for five minutes. The indicated amounts of extracellular domains of recombinant VEGF R2 (Catalog # 357-KD), VEGF R1 (Catalog # 321-FL) or VEGF R3 (Catalog # 349-F4) were added to 100 μg lysate and analyzed by this ELISA. Competition was observed only with recombinant VEGF R2. |
Citations for Human Phospho-VEGFR2/KDR DuoSet IC ELISA (12)
Showing
1
-
10 of
12 citations
Showing All
Filter By:
Search Title:
Citations are publications that use Bio-Techne products. Selected citations for Human Phospho-VEGFR2/KDR DuoSet IC ELISA include:
-
Species: Human
Sample Types: Cell Lysates
T Yao et al. (2022-06-08), Thiol-ene conjugation of VEGF peptide to electrospun scaffolds as potential application for angiogenesis Bioactive materials, 2022-020(0):306-317.
PMID: 35755423 -
Species: Human
Sample Types: Cell Lysates
L Koehler et al. (2019-12-02), Dual Action of Sulfated Hyaluronan on Angiogenic Processes in Relation to Vascular Endothelial Growth Factor-A Sci Rep, 2019-19(1):18143.
PMID: 31792253 -
Species: Human
Sample Types: Whole Cells
P Mésange et al. (2018-02-28), Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status Clin. Cancer Res., 2018-00(0).
PMID: 29490990 -
Species: Human
Sample Types: Cell Culture Supernates
M Su et al. (2017-11-23), Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway Drug Des Devel Ther, 2017-111(0):3333-3341.
PMID: 29200829 -
Species: Human
Sample Types: Cell Lysates
Raquel Costa (2017-01-30), Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay Mol Nutr Food Res, 2017-00(0).
PMID: 27921359 -
Species: Human
Sample Types: Cell Lysates
Harris et al. (2013-02-12), The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem, 2013-0288(12):8176-86.
PMID: 23404505 -
Species: Human
Sample Types: Cell Lysates
Gavine PR et al. (2012-02-27), AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res., 2012-072(8):2045-56.
PMID: 22369928 -
Species: Human
Sample Types: Cell Lysates
Yamashita-Kashima Y et al. (2012-01-25), Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer, 2012-012(0):37.
PMID: 22273502 -
Species: Human
Sample Types: Cell Lysates
Martino MM et al. (2010-07-29), The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J., 2010-024(12):4711-21.
PMID: 20671107 -
Species: Human
Sample Types: Cell Lysates
Xu Y et al. (2010-01-11), Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol., 2010-0188(1):115-30.
PMID: 20065093 -
Species: Human
Sample Types: Cell Lysates
Pan Q et al. (2007-06-16), Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem., 2007-0282(33):24049-56.
PMID: 17575273 -
Species: Human
Sample Types: Cell Lysates
Favier B et al. (2006-04-18), Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood, 2006-0108(4):1243-50.
PMID: 16621967
There are no citations that match your criteria.
FAQs for Human Phospho-VEGFR2/KDR DuoSet IC ELISA
-
Which phosphorylated sites are recognized by this assay?
This assay utilizes an anti-phosphorylated tyrosine monoclonal detection antibody, and it recognizes all phosphorylated tyrosine residues.
-
Is it possible to obtain quantitative data from Human Phospho-VEGFR2/KDR DuoSet IC ELISA?
Human Phospho-VEGFR2/KDR DuoSet IC ELISA is a developmental ELISA designed to be semi-quantitative for detecting relative changes in sample phosphorylation. End users can optimize this kit to be quantitative. It is possible to construct a standard curve from the control provided in the kit. The linear bounds would need to be empirically verified by the end user as R&D Systems has not tested this optimization in-house.
